The MAP kinases Erk1/2 are the major mediators of the oncogenicity of the Receptor tyrosine kinase (RTK)-Ras-Raf-MEK cascade. As components of this pathway are often mutated and constantly active in cancer, Erks are regarded as promising targets for therapy for many types of malignancies. Yet, while...
ORGANISM(S): Mus musculus (Mouse)
